Search

everythinglearnresearchcommunity

for

Search:↓

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

LPA3 is crucial for embryo implantation and links LPA to prostaglandin signaling.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.

Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Some synthesized peptides improved cell growth better than thymosin β4, VEGF, and minoxidil.

GLP-1 receptor agonists may cause hair loss, but regrowth is rare.

Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Peptide drugs now target hard-to-reach proteins more effectively and specifically.

Triptorelin helps evaluate hormone production in Sertoli-Leydig cell tumors.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

Using a certain drug on the skin can help prevent hair loss caused by pulling on the hair.

TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.

Prostaglandin F2alpha and related compounds can increase hair growth and darken hair in mice.

Adding a second method to PROTACs could improve cancer treatment.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Hormone-replacement therapy improved a woman's skin condition known as lymphomatoid papulosis.